Your Guide to Covid-19 Vaccine Stakeholders’ IP Strategies
Public attention on potential obstacles to the widespread and affordable distribution of immunisations will continue to intensify. That means rights holders’ approaches to the protection and commercialisation of their covid-19 products will face heightened scrutiny from the public and governments.
Several small molecule drug owners have waived exclusive rights to their potential repurposed covid-19 treatments. Not only has AbbVie promised not to enforce its patents for Kaletra, but Novartis committed to making all IP relating to possible covid-related uses of hydroxychloroquine available on a no-fee basis. Gilead rescinded a request for regulatory exclusivity for remdesivir and signed non-exclusive licensing deals with five generic companies to produce and sell the drug in 127 lower-income countries.
Source: Law Business Research